Evicenter
Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in Herpes zoster prevention
Manufacturer
GlaxoSmithKline Biologicals; GlaxoSmithKline
Prescribing information
Shingrix (opens in a new tab)
Questions
47
Last updated

All questions

Guidelines: Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention

4 questions · 2 sources

Guidelines

Does the CDC recommend Shingrix for adults 50 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: The recommendation is as stated in the manufacturer's Shingles Vaccine Recommendations guide (dated April 2026), which cites the CDC shingles vaccine recommendations web page accessed May 31, 2025.

Does the CDC recommend Shingrix for immunocompromised adults 19 and older?

Applies to Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

Note: The CDC Recommendations page of the immunocompromised section of the Shingrix HCP site presents this recommendation under the heading "CDC Recommends:" and cites the 2022 ACIP recommendations (MMWR). The CDC recommendation covers adults 19 and older; the Prescribing Information indication covers adults 18 and older.

Shingrix and diabetes: what do ADA and AACE guidelines recommend?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: As presented in the manufacturer's Shingles Vaccine Recommendations guide (April 2026): the ADA statement concerns zoster vaccination and the AACE statement concerns recombinant zoster vaccine (RZV); the guide cites the ADA Standards of Care in Diabetes 2025 and the AACE 2022 clinical practice guideline.

Shingrix and COPD: what does the GOLD report recommend?

Applies to Prevention of herpes zoster (shingles) in adults aged 50 years and older

Note: As presented in the manufacturer's Shingles Vaccine Recommendations guide (April 2026): the GOLD statement concerns zoster vaccination in general; the guide cites the 2025 GOLD report.